Steve

- Silent in the bloodstream. Active in the tumor.
- A once in a lifetime opportunity...!

[RAH @RAH00084]

@PJ_Crabb Quite. Anyone moaning about this one needs to give their heads a wobble.

#AVCT is replacing Heights with institutional investors.

That is exactly what everyone has been craving for many years.

Remarkable lack of reaction so far.

[Steve @STWpharma]

I read it like this too. In essence, CC is claiming that the beast is doing what it is supposed to do, which is winning!

Could this be a an indication that the beast is doing well? Imo, yes.

#avct

[Mark Mitchell @emily1katie]

#AVCT - Essentially saying we expect 6103 to work! 💥

[TVR5 @TVR5AVCT]

An expectation of “seeing something” (clinical activity) will be informed by the 1,000+ public patient data bank on free Exatecan + the extensive data set on Deruxtecan (Enhertu).

#AVCT designing AVA6103 in this way suggests the trial is as of today in its most pivotal period.

[stonks @JStonker]

"Not enough patients have experienced disease progression for us to be able to calculate median PFS."

#AVCT

[TVR5 @TVR5AVCT]

#AVCT

“We’re hoping we see something more in the
middle range of our dose levels”

[AM23 @AM231982]

Avacta #AVCT has a very bright future.

In recent weeks they have openly compared AVA6103 preclinical data to Enhertu and Datroway both multi billion $ drugs only weeks into the actual human trial.....That is how you poke a bear!

There is a long list of positive news items coming up fast. In no particular order.

1. SGC Fast Track approval & PFS data
2. SGC commercial deal
3. First ever data on TNBC for AVA6000
4. Full AVA6000 deal
5. SAB - Representation for specialists for all the 6 indications in the AVA6103 trial
6. New Chairman
7. AVA6207 - Dual warhead deals - Multiple possible
8. Peer reviewed data
9. 5 new sites expected for AVA6103 trial just in P1A (up to 17 more to support the next stage also)
10. Bio International conference later this month.

All of these in the coming weeks are possible. It will change this company forever. Deals Deals Deals are on the menu.

[Marty McFly @Blueberrymgmnt]

“Released doxorubicin enters plasma gradually following FAP-mediated cleavage in the TME, eliminating the sharp systemic peaks typical of conventional dosing.”

The first time #AVCT has concluded how AVA6K works.

Slow, gradual ‘spill over’ ➡️ Released only once cleaved by FAP.

[Paradigm Coaching @ParadigmCoachi1]

@RAH00084 It's truly staggering how big the disconnect between the market and the data is. That RNS is blockbuster. 92% DCR is outstanding, and still no median PFS. AVA6000 (as we've expected for years) shows the platform works. AVA6103 is going to be REALLY exciting. #AVCT

[RAH @RAH00084]

#AVCT cut data 15 May

“The disease control rate remains consistent at 92% (35/38)”

“Nine patients are continuing treatment, and a further 11 patients remain in follow up for disease progression.”

“The study continues to enroll patients”

So, still no final PFS.

Remarkable.

[Christina Coughlin @coughlin582]

The #AVCT team is a very special group of people as you have seen from Science Day 2026. One of our employees left today (for good reasons!) and wrote a haiku that was so poignant. This is the team delivering our next chapter

#ThisIsTheTeam
#HopeWithoutCompromise
#LetsDoThis

[Richard Hughes @hughesy0707]

In my personal view 2026 will be a defining point for #AVCT and ultimately for long term cancer patients.

Thanks to all shareholders and stakeholders for their support.

[Steve @STWpharma]

@hughesy0707 Welcome aboard, Richard. As a shareholder, this is exactly what we want to hear. The confidence in the preCISION IP and the team is highly reassuring. Wishing you and the team every success in maximizing this value.

[RAH @RAH00084]

#AVCT shareholders will feel the full impact of this appointment not today but when the board is deciding which offer to recommend to shareholders.

Board now ultra lean. Coughlin, Hughes + x3 NEDs. No bloat. Little waste.

Unrecognisable from 12 months ago.

[Cumulus @Cumulus51896691]

If Avacta's preCISION technology reaches 90% of solid tumours, around three quarters have no available targeted ADC treatment. Recent comparisons with Enhertu are a benchmark not a threat. preCISION drugs could treat millions without taking a single patient from them. #avct

[RAH @RAH00084]

#AVCT

[RAH @RAH00084]

@Blueberrymgmnt 💯

Roll on AVA6103

#AVCT

[Marty McFly @Blueberrymgmnt]

@RAH00084 The standout feature of the Phase 1 data is its remarkable consistency and predictability. The PK parameters established today are highly likely to extrapolate reliably, underscoring a position that remains massively underappreciated. #AVCT

[RAH @RAH00084]

You’re quoting AI which says the “main data drop already happened on May 21”.

Hopefully(!) most #AVCT shareholders know that isn’t accurate.

Pipeline drivers:

💉AVA6000

✅ PFS reveal in SGC (assume ASCO)

✅ TNBC data (assume separate conference)

✅ cardiac data

✅ Fast Track or other expedited FDA route on SGC (again, we will get it because the criterion for it is identical to lifting the dosing limit). See Scancell’s performance since announcing Fast Track.

✅ Deal (SGC only or package with TNBC)

💉AVA6103

✅ multiple levers the CEO can pull to confirm the Gen2 tech is working. When asked she said in side discussion at SD she wasn’t averse to RNS’ing individual patient responses, but it all depends on whether it makes strategic sense (read: commercials and NDA discussions etc)

As for how good those P1a responses are remains to be seen but shareholders should note the Enhertu P1a results (NCT02564900):

Doses tested: 0.8 to 8.0 mg/kg

23 patients

Zero complete responses.

10 partial responses.

Crucially, 9 of the 10 responses occurred at doses of 5.4 mg/kg or higher.

This is why BOIN is so important to AVCT.

💉AVA6207

Deal on AVA6207 and you have third party validation of AVA6103.

Crucially, one deal on 6207 makes a second more likely. A second makes a third inevitable.

Disclosure of warheads is a critical juncture on their swim lane for good reason.

The company’s strategy - and navigation of this critical period - remains extremely shrewd. Even if it doesn’t sit well with the ‘when we gonna get there’ brigade.

Many (well researched) SH remain unable to separate old strategy from new. Previous mgmt from current. What was best THEN to what is best NOW.

Feet up. Different company.

[stonks @JStonker]

#AVCT coverage published yesterday.

https://t.co/NyqCXEFgw5

[JONNO @Jonno981]

#avct conviction never higher. AVA6103 Phase 1 data H2 2026. Pre|CISION platform outperforming leading ADCs in head 2 head preclin data. FAP exp across multiple solid tumours = not single indication story. Gilead paid $21B for Immuno with 1 drug. Pfizer paid $43B for Seagen